State Street (STT) Offering Possible 12.61% Return Over the Next 15 Calendar Days

State Street's most recent trend suggests a bullish bias. One trading opportunity on State Street is a Bull Put Spread using a strike $85.00 short put and a strike $80.00 long put offers a potential 12.61% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $85.00 by expiration. The full premium credit of $0.56 would be kept by the premium seller. The risk of $4.44 would be incurred if the stock dropped below the $80.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for State Street is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for State Street is bullish.

The RSI indicator is at 37.1 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for State Street

An Investor Just Bought $122 Million of State Street's Junk ETF
Tue, 31 Jul 2018 17:40:30 +0000
At least one investor appears to be bingeing on junk bonds.

Gains in the State Street Global Exchange Private Equity Index Slow for First Time in Two Years
Tue, 31 Jul 2018 17:22:00 +0000
The State Street Global Exchange® Private Equity Index (GXPEI) ended the first quarter of 2018 with a slight increase of 2.44 percent. The Buyout funds category ended its streak of eight quarters of outperformance with a 2.09 percent gain, lagging behind the 3.78 percent return from Venture Capital funds and 2.46 percent from Private Debt funds. The PEI is based on directly-sourced limited partnership data and represents more than $2.8 trillion in private equity investments, with more than 2,800 unique private equity partnerships, as of March 31.

Former State Street executive avoids prison in U.S. fraud case
Tue, 31 Jul 2018 17:20:08 +0000
A former State Street Corp executive avoided prison on Tuesday after cooperating with U.S. authorities investigating a scheme to defraud clients of the bank by applying secret commissions on billions of dollars in securities trades. Richard Boomgaardt, who was the head of State Street’s transition management desk for Europe, the Middle East and Africa, faced up to five years in prison after pleading guilty in 2017 to conspiring to commit wire fraud and securities fraud.

State Street Joins Morgan Stanley in Calling End of Dollar Rally
Tue, 31 Jul 2018 13:23:17 +0000
The U.S. dollar rally is just about finished, according to a growing chorus of Wall Street forecasters. Morgan Stanley, State Street Corp. and Wells Fargo & Co. are some of the prognosticators saying the greenback is near its peak after gaining around 5 percent since mid-April. Currency jawboning by U.S. President Donald Trump, shifting growth expectations outside America, and tweaks to central-bank policies are among the bearish factors that could drive the greenback lower in the coming months, analysts said.

Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines — Future Expectations, Projections Moving into 2018
Tue, 31 Jul 2018 11:40:00 +0000
NEW YORK, July 31, 2018– In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amicus …

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.